HIV & immune reconstitution inflammatory syndrome (IRIS)

Area of Science:

• Immunology
• Infectious Diseases
• HIV/AIDS Research

Background:

• Antiretroviral therapy (ART) improves immune function in HIV patients, reducing opportunistic infections.
• However, a subset of patients develop immune reconstitution inflammatory syndrome (IRIS) due to dysregulated immune responses post-ART initiation.
• IRIS presents as a paradoxical worsening or new onset of infections after therapy begins.

Purpose of the Study:

• To describe the phenomenon of IRIS, its characteristics, and implications in HIV management.
• To highlight the unclear immunopathogenesis and ongoing research into biomarkers for IRIS.
• To discuss the clinical course, management strategies, and prognosis of IRIS.

Main Methods:

• Literature review and synthesis of existing knowledge on IRIS in HIV-infected patients.
• Analysis of clinical presentations, common causative agents, and diagnostic challenges.
• Examination of treatment approaches and prognostic factors associated with IRIS.

Main Results:

• IRIS incidence varies based on population and opportunistic infection burden.
• Unbalanced T-cell reconstitution is implicated in IRIS immunopathogenesis.
• Common IRIS forms involve mycobacterial, fungal, and herpes viral infections.
• Most IRIS cases are self-limiting, with low overall mortality.
• Central nervous system and respiratory involvement indicate poor prognosis.

Conclusions:

• IRIS is a significant concern in HIV management, especially in resource-limited settings with high opportunistic infection rates.
• Earlier ART initiation may decrease IRIS burden in developed nations.
• Aggressive management, including corticosteroids, is crucial for severe IRIS cases.
• Continued research into biomarkers and immunopathogenesis is essential for improved IRIS prediction and treatment.